A new chapter in agricultural biotechnology has opened with the U.S. Food and Drug Administration´s approval of CRISPR-edited pigs designed to resist porcine reproductive and respiratory syndrome (PRRS), a deadly virus that has plagued American pig farms. Developed by British firm Genus, these pigs represent one of the first genetically modified animals cleared for human consumption, joining a select group that previously faced daunting regulatory and economic hurdles.
Genus engineered the pigs by editing embryos to remove a critical receptor used by the PRRS virus to infect cells, rendering the animals immune to over 99% of known virus variants. This approach leverages gene editing to alter the animal´s own DNA without introducing foreign genetic material, distinguishing it from earlier genetically modified organisms like transgenic salmon. Besides the technical accomplishment, the expected impact is substantial, as PRRS causes significant economic losses in the pork industry annually.
Gene editing in livestock has broader implications for both food security and public health. While past high-profile efforts, such as the controversial CRISPR-edited babies in China, drew global criticism, the ethical and financial calculus for farm animals is distinct. The Genus pigs not only promise to save billions in losses but could also reduce the risk of zoonotic disease transmission. Research continues to expand genetic resistance to other livestock illnesses, including African swine fever and influenza, which carry pandemic potential. Although there is no current U.S. requirement for labeling gene-edited pork, market entry will depend on securing approvals from key trading partners, and Genus anticipates domestic availability could begin next year. The development underlines the growing capabilities of gene editing and its role in creating resilient, efficient food systems.
